Shareholdings
| Concept |
As at 2019-03-31 |
As at 2019-03-31 |
As at 2019-03-31 |
As at 2019-03-31 |
As at 2019-03-31 |
As at 2018-03-31 |
As at 2018-03-31 |
As at 2018-03-31 |
As at 2018-03-31 |
As at 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shareholdings | ||||||||||
| Reporting company | ||||||||||
| Details of specified investment shares held for purposes other than pure investment | ||||||||||
| Issue |
ANTARES PHARMA,INC.
|
持田製薬㈱
|
㈱三菱UFJフィナンシャル・グループ
|
㈱みずほフィナンシャルグループ
|
㈱三井住友フィナンシャルグループ
|
— | — | — | — | — |
| Number of shares |
xbrli:shares
|
102,000
xbrli:shares
|
xbrli:shares
|
xbrli:shares
|
xbrli:shares
|
354,150
xbrli:shares
|
29,930
xbrli:shares
|
1,976
xbrli:shares
|
944
xbrli:shares
|
102,000
xbrli:shares
|
| Carrying amount |
JPY
|
1,163,000,000
JPY
|
JPY
|
JPY
|
JPY
|
67,000,000
JPY
|
20,000,000
JPY
|
0
JPY
|
4,000,000
JPY
|
762,000,000
JPY
|
| Purpose of shareholding |
|
事業利回りならびに配当利回りに対する当社資本コストの比較検証。
|
|
|
|
— | — | — | — | — |